Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based Celator Pharmaceuticals has appointed Scott Jackson as the company's new CEO. Mr Jackson succeeds Andrew Janoff.
Subscribe to our email newsletter
Mr Jackson joined Celator in October 2007 as head of commercial development. Mr Jackson has extensive experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing, and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems, Centocor (Johnson & Johnson), Eximias Pharmaceuticals and YM BioSciences.
Mr Jackson holds a BS in Pharmacy from the Philadelphia College of Pharmacy and Science and an MBA from the University of Notre Dame.
Joseph Mollica, chairman of Celator’s board of directors, said: “Scott’s senior management experience and commercial and clinical development knowledge will be extremely valuable to the organization as the company moves forward.”